Trial results for the study NCT03557359 investigating nivolumab for recurrent or progressive IDH mutant gliomas were posted on ClinicalTrials.gov on 2025-11-03. The study reported an overall response rate of 9 percent in participants treated with nivolumab.
Background
The study, titled "Nivolumab for Recurrent or Progressive IDH Mutant Gliomas," aimed to evaluate the response rates (partial and complete responses) to nivolumab in patients with recurrent or progressive IDH mutant gliomas of grades 2, 3 or 4, who had prior exposure to alkylating agents.
Trial design
The study NCT03557359 was a Phase 2, single-arm trial that enrolled 35 participants. The trial investigated nivolumab as an intervention for individuals with recurrent or progressive IDH mutant gliomas (grades 2, 3 or 4). The primary objective was to determine the overall response rates, including partial and complete responses, in this patient population, specifically those with prior exposure to alkylating agents.
Key results
For the outcome of "Overall Response Rate" in the nivolumab treatment group, the study reported a rate of 9 percent.
What this means
The reported overall response rate of 9 percent for nivolumab in recurrent or progressive IDH mutant gliomas with prior alkylating agent exposure provides initial data on the activity of this therapy in a challenging patient population. These results contribute to the understanding of potential therapeutic options for patients who have experienced disease progression after prior treatments and highlight the need for further research into effective strategies for these specific glioma subtypes.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03557359, titled "Nivolumab for Recurrent or Progressive IDH Mutant Gliomas," were posted on 2025-11-03 on clinicaltrials.gov.